

Increased Protein and Lipid Oxidative Damage in Mitochondria Isolated from Lymphocytes from Patients with Alzheimer's Disease: Insights into the Role of Oxidative Stress in Alzheimer's Disease and Initial Investigations into a Potential Biomarker for this Dementing Disorder

Rukhsana Sultana^a, Patrizia Mecocci^b, Francesca Mangialasche^b, Roberta Cecchetti^b, Mauro Baglioni^b and D. Allan Butterfield^{a,*}

^a*Department of Chemistry, Center of Membrane Sciences, and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA*

^b*Department of Clinical and Experimental Medicine, Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy*

Handling Associate Editor: William Banks

Accepted 5 November 2010

Abstract. Alzheimer's disease (AD) is histopathologically characterized by the presence of senile plaques, neurofibrillary tangles, and synapse loss. The main component of senile plaques is amyloid β -peptide ($A\beta$), which has been shown to induce oxidative stress in *in vitro* and *in vivo* studies. AD is associated with elevated levels of oxidative damage in brain and peripheral lymphocytes. Further $A\beta$ has been found to be accumulated in mitochondria, which might contribute to the reported alterations in the mitochondrial morphology, and impaired mitochondrial energy metabolism in AD brain. Biomarkers are desperately needed for earlier diagnosis of AD and to monitor efficacy of new therapies. Hence, in the present study we show that markers of oxidative damage are elevated in mitochondria isolated from AD lymphocytes suggesting that these oxidative stress indices potentially could serve as a viable biomarker for AD.

Keywords: Alzheimer's disease, lymphocytes, mitochondria, 3-nitrotyrosine, oxidative stress, protein-bound 4 hydroxy-2 *trans* nonenal, protein carbonyls

INTRODUCTION

Free radicals are produced in a low amount in the body as a process of natural metabolism. Free radicals are also formed by a tightly coupled and regulated process during oxidative phosphorylation, thereby playing

*Correspondence to: Professor D. Allan Butterfield, Department of Chemistry, Center of Membrane Sciences, and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40506-0055, USA. Tel.: +1 859 257 3184; Fax: +1 859 257 5876; E-mail: dabcs@uky.edu.

an important role in energy (ATP) production. Some of the free radicals, like nitric oxide, are important in regulating signaling processes within the cells, and some free radicals are used by the immune system to destroy invading pathogens. Hence, balanced levels of free radicals are important for normal cellular function, and they are normally checked in the body by the antioxidant defense system. When the levels of the free radicals exceed the limit that can be combated by cellular defense mechanisms, a phenomenon referred to as "oxidative stress" ensues. Oxidative stress occurs due to an imbalance in the levels of oxidants and antioxidant systems that could result from either an increase in the levels of oxidants or a decrease in the levels of antioxidant enzymes.

Mitochondria represent a main source of free radicals, particularly of the superoxide radical that can be dismutated by Mn superoxide dismutase (SOD) to produce hydrogen peroxide. In its protonated, non-charged form, HO_2 can diffuse freely across the membrane and is a likely candidate that can attack and damage biomolecules at a distant site. Moreover, hydrogen peroxide in the presence of redox-active metals like iron or copper may lead to the production of hydroxyl radicals that are highly reactive with a short half-life of seconds. Hence $\bullet\text{OH}$ radical can affect adjacent biomolecules inside mitochondria. Further, the degradation of the damaged mitochondria by autophagy and consequent release of heme iron into the cytosol also can contribute to free radical elevation [1], which can attack proteins, lipids, carbohydrates, and nucleic acids leading to altered cellular function and consequent cell death.

Alzheimer's disease (AD) is histopathologically characterized by the presence of senile plaques, neurofibrillary tangles, and synapse loss [2]. The main component of senile plaques is amyloid- β peptide ($\text{A}\beta$), which is generated by the cleavage of amyloid- β protein precursor ($\text{A}\beta\text{PP}$) by β - and γ -secretases. $\text{A}\beta$ has been shown to induce oxidative stress in a number of *in vitro* and *in vivo* studies [3–6] and, on the other hand, oxidative stress can increase production of $\text{A}\beta$ [7]. A large number of studies have shown increased levels of oxidative markers of biomolecules (protein, lipids, carbohydrates, and nucleic acids) in AD brain and peripheral systems [8–17]. Further, increasing evidence implicates $\text{A}\beta$ accumulation in mitochondria in AD [18–21].

Biomarkers are desperately needed for earlier diagnosis of AD and to monitor efficacy of new therapies [22]. Currently, there are no agreed upon biomarkers that serve these purposes, especially in the earli-

est form of AD, i.e., mild cognitive impairment (MCI).

Although most of the studies on oxidative biomarkers have been performed in brain, several studies have demonstrated that oxidative stress phenomena can also be detected in peripheral tissues [23, 24]. In the present study, in order to begin to evaluate potential biomarkers for AD, we have measured indices of protein oxidation and lipid peroxidation in mitochondria isolated from lymphocytes of cognitively healthy and AD subjects.

MATERIALS AND METHODS

Subjects

Subjects were enrolled at the Memory Clinic of the Institute of Gerontology and Geriatrics, University of Perugia. Nine subjects (2 males, 7 females, mean age 80.1 ± 8.1) with a Mini-mental state examination (MMSE) score [25] ranging from 16 to 22 fulfilled the NINCDS-ADRDA criteria for AD [26]. Eleven (3 males, 8 females, mean age 80.1 ± 4.7) were cognitively normal subjects (MMSE 29–30).

All subjects were evaluated according to a standard protocol including a detailed anamnesis, clinical, and neuropsychological evaluation. Subjects with a history of having a smoking habit and/or alcohol abuse, major organ failure, dyslipidemia, or metabolic alterations were not included. After giving informed consent, patients and controls underwent a 20 ml blood sample withdrawal. Samples were immediately processed for mitochondria isolation.

Materials

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. The Oxyblot oxidized protein kit was obtained from Interger, Inc. (Purchase, NY). Primary antibodies for 4-hydroxynonenal (HNE) and 3-nitrotyrosine (3-NT) were obtained from Chemicon (Temecula, CA).

Isolation of mitochondria

Freshly obtained blood was layered on Lymphoprep (Gibco, BRL, Bethesda, MD), centrifuged and washed twice. The pellet was resuspended in 400 μl of ice-cold PBS. Eight μl of 2.5% digitonin were added and kept on ice for 5 min inverting gently every 30 s. Each sample was sonicated for 1 min and then centrifuged at 600g for 10 min at 4°C to eliminate nuclei and unbro-

ken cells. The supernatant was centrifuged at 14,000g for 10 min at 4°C, the pellet resuspended in 400 µl ice cold PBS and centrifuged at 7,000g for 10 min at 4°C. The pellet was resuspended in 400 µl ice cold PBS and centrifuged at 3,500g for 10 min at 4°C. The pelleted purified mitochondria were immediately frozen and kept at -80°C until analyses.

Protein carbonyl measurement

Protein oxidation was determined by an oxidized protein detection kit (Oxyblot; Chemicon) [27]. Briefly, 5 µl of mitochondria (4 mg/ml) were incubated for 20 min with 12% sodium dodecyl sulfate (SDS) and 2,4-dinitrophenylhydrazine (DNPH) followed by addition of 7.5 µl of neutralization solution. The derivatized proteins (250 ng) were transferred onto nitrocellulose membrane by the slot blot technique. Membranes were incubated with blocking buffer for 60 min at 27°C and incubated with rabbit antibodies to DNPH (diluted 1 : 150) for 90 min, then by anti-rabbit IgG coupled to alkaline phosphatase (1 : 10,000) for 1 h at 27°C. After being washed and developed with SigmaFast chromogen (Sigma), blots were scanned into Adobe Photoshop (Adobe Systems, Inc., Mountain View, CA) and quantitated with Scion Image (PC version of Macintosh-compatible NIH Image).

3-Nitrotyrosine levels

Protein-bound 3-NT was determined by incubating the samples (5 µl) with Laemmli buffer (10 µl) (0.125 M Trizma base, pH 6.8, 4% SDS, 20% glycerol) for 20 min. Samples (250 ng of protein) were blotted onto nitrocellulose membranes, and immunochemical methods were performed [27]. The rabbit anti-3-NT primary antibody was incubated 1 : 200 in blocking buffer [bovine serum albumin (BSA) 3% in TBS-T] for 2 h. The membranes were washed three times with TBS-T and incubated with alkaline phosphatase-conjugated goat anti-rabbit secondary antibody (1 : 10,000). Densitometric analysis of bands in images of the blots was used to calculate levels of 3-NT.

Lipid peroxidation

4-Hydroxy-2-nonenal (HNE), a lipid peroxidation marker, was measured as an index of lipid peroxidation [27]. The samples (5 µl) were incubated with 10 µl Laemmli buffer for 20 min at room temper-

ature, and 250 ng of protein samples was loaded into each well on nitrocellulose membrane in a slot blot apparatus under vacuum. The membranes were incubated with anti-HNE rabbit polyclonal antibody (1 : 5,000) for 2 h, washed three times with TBS-T, and then incubated with an anti-rabbit IgG alkaline phosphatase-conjugated secondary antibody (1 : 10,000). Blots were developed with SigmaFast tablets (BCIP/NBT), dried, and quantified in Scion Image.

Statistical analysis

Two-tailed, Student's *t*-tests were used to analyze differences in oxidative stress markers between AD and age-matched controls samples. A *p*-value of less than 0.05 was considered statistically significant.

RESULTS

Reactive oxygen and nitrogen species can attack polyunsaturated fatty acids of lipid bilayers leading to the formation of reactive aldehydes, among which one of the most toxic products is HNE [15, 28]. HNE can react with proteins leading to the formation of stable covalent adducts with histidine, lysine, and cysteine residues via Michael addition [29–30]. Figure 1A shows the HNE-bound protein levels in mitochondria isolated from AD lymphocytes are significantly increased compared to control (***p* < 0.001). Further, the levels of protein-bound HNE did not show any significant correlation with MMSE score (Fig. 1B), although we observed a trend towards a negative correlation with MMSE score (**p* < 0.07, Table 1), suggesting that the increase of protein-bound HNE might reflect the decrease in cognitive functions.

Protein carbonyls and 3-NT levels were measured as markers of protein oxidation [31]. Protein carbonyl groups are generated by direct oxidation of certain amino acid side chains, peptide backbone scission, by Michael addition reactions with products of lipid peroxidation, or glycoxidation [29–31]. Oxidative stress also could stimulate additional damage via the over expression of inducible nitric oxide synthase (iNOS) and the action of constitutive neuronal NOS (nNOS), both of which lead to increased levels of 3-NT. Levels of protein carbonyls (*p* < 0.02) (Fig. 2A), and 3-NT (*p* < 0.03) (Fig. 3A) were significantly increased in AD lymphocyte mitochondria compared to controls. The levels of protein carbonyls, and protein-bound 3-NT showed significant (*p* < 0.05, Figs 2B, 3B) negative correlation with MMSE score, suggesting that the increase




Fig. 1. Increased levels of protein-bound HNE were observed in mitochondria isolated from lymphocytes from AD patients compared to those of respective controls (A). Protein-bound HNE data are represented as arbitrary units, * $p < 0.001$. Linear correlation analysis between protein-bound HNE and MMSE did not show any significant correlation (B) ($p < 0.07$), though a trend toward a significant negative correlation was observed (see text).

Table 1

Correlation analysis between oxidative stress markers and MMSE score (all 20 subjects included): for oxidative stress parameter, we report the R^2 value and the corresponding p value

Oxidative stress markers	R^2	p -value
Protein-bound HNE	-0.39	0.07*
Protein carbonyls	-0.5	0.02
Protein bound 3-NT	-0.49	0.02

*No significant correlation was found (p threshold set at 0.05).

of protein carbonyls and protein-bound HNE might reflect the decrease in cognitive functions. The ' R^2 values' and ' p values' for the linear correlation analysis are shown in Table 1.

DISCUSSION

This work provides the first report of increased levels of oxidative stress in the mitochondria isolated from lymphocytes of AD subjects compared to those of controls as indexed by elevated levels of protein carbonyls, protein-bound HNE and protein-resident 3-nitrotyrosine. Elevation of oxidative stress markers in AD lymphocyte mitochondria is consistent with the decreased plasma levels of GSH and increased levels of GSSG in AD lymphocytes, and consequent lower ratio of GSH/GSSG previously reported [32]. Further, this same study also showed that the levels of heme oxygenase-1 and activity and the levels




Fig. 2. Increased levels of protein carbonyls were observed in mitochondria isolated from AD compared to respective controls. A) Protein carbonyl data are represented as arbitrary units, * $p < 0.02$. B) A significant negative correlation was observed between the protein carbonyl levels and MMSE scores ($p < 0.02$).




Fig. 3. Increased levels of protein bound-3 nitrotyrosine (3-NT) were observed in mitochondria isolated from AD compared to respective controls. A) Protein bound 3-NT data are represented as arbitrary units, * $p < 0.03$. B) A significant negative correlation was observed between the protein bound 3-NT levels and MMSE scores ($p < 0.02$).

of NOS-2, HSP72, HSP60, and thioredoxin reductase were elevated in AD lymphocytes [32], consistent with an oxidative environment. Using HPLC analysis, AD patients were shown to have significantly higher lymphocyte concentrations of the oxidized purine 8OHdG than do controls [33]. Moreover, the levels of plasma antioxidants such as lycopene, lutein, α -carotene, and β -carotene, were found to be significantly lower in patients with AD compared with controls and showed an inverse relationship to lymphocyte DNA 8-OHdG content [10]. The imbalance in the levels of antioxidants and increase levels of oxidative insult conceivably could be due to A β in the plasma of AD subjects. However, studies related with plasma A β levels showed contradictory results. A study conducted by Xu and colleagues [34] showed that the A β ₁₋₄₀ level is increased and A β ₁₋₄₂ is decreased, in contrast to others who showed no differences in A β levels [35, 36] or increased A β ₄₂ in AD patients [37]. These differences could be due to variation of experimental conditions.

As noted above, A β is produced from the proteolytic cleavage of a transmembrane A β PP by the sequential actions of the aspartate proteases β - and γ -secretase [2]. A number of *in vitro* and *in vivo* studies showed that A β can induce oxidative stress [4–6]. Further, A β has been shown to exist in various aggregated states, among which are monomers, oligomers, protofibrils, and fibrils. The oligomeric form of A β is considered a highly toxic species of A β [38]. Recent studies reported the presence of A β in mitochondrial membranes [19, 20]. The localization of A β in the mitochondria suggest that it may initiate lipid peroxidation in the mitochondrial mem-

brane by similar processes as discussed above, leading to alterations in components of the membrane such as lipid and proteins, including the electron transport system. These alterations, in turn, can lead to alterations in membrane fluidity, leakage of apoptosis-inducing molecules such as cytochrome C and apoptosis inducing factor from the mitochondria, all of which may contribute to decreased cellular energetics, neuronal apoptosis, and generation of reactive oxygen species in AD. In contrast, a previous study showed that the activities of respiratory chain enzymes in mitochondria isolated from lymphocytes of AD patients did not demonstrate any significant differences [39].

There is ample evidence of increased oxidative stress in AD brain and in fibroblasts from sporadic AD subjects [7, 15, 20, 40]. Alterations in the mitochondrial morphology and impaired mitochondrial energy metabolism have been well documented in AD brain [18, 20, 41]. Further, a number of studies suggest that there is decreased rate of cerebral metabolism in AD brain. The reduced level of cerebral metabolism has been also found in pre-AD stages, such as MCI and early AD (EAD), as revealed by PET studies [42]. Previous studies from our laboratory using proteomics have identified a number of proteins associated with glucose metabolism that are oxidatively modified and dysfunctional proteins [20, 43–49]. The decrease in the cerebral energy reported in AD brain by PET studies correlated with the altered expression and decreased activity of mitochondrial energy-related proteins such as pyruvate dehydrogenase complex (PDHC), α -ketoglutarate dehydrogenase complex (KGDHC), and isocitrate dehydrogenase [50]. Further, decreased glucose utilization has been reported in skin fibroblasts

of AD patients [51], and *in vitro* studies reported that incubation of isolated mitochondria with A β peptides decreased the activity of KGDHC and PDHC [52].

The assessment of a subject's cognitive function is used as one criterion for clinical diagnosis of AD. Thus, a better understanding of how the MMSE score relates to mitochondrial oxidative stress markers in the lymphocytes isolated from control and AD was obtained by linear correlation analysis. Our finding of a negative correlation of oxidative stress markers, such as protein carbonyls and protein-bound 3-NT, to MMSE score suggests that low MMSE scores characteristic of AD correlate with increased oxidative stress markers in the peripheral system reflecting oxidative damage to the central nervous system. A previous study by Montine and coworkers [53] showed no significant difference in the product of lipid peroxidation such as iso-prostanol and neuroprostanol in plasma; however, data presented in this study showed increased levels of protein-bound HNE in the mitochondria isolated from lymphocyte of AD and shows a trend toward negative correlation to the MMSE score, consistent with our findings reported in the present study. In the plasma, certain proteins like albumin are present in relatively high abundance which can mask the precise determination of oxidative stress markers in plasma, thereby limiting the discovery of biomarker in the plasma. However, by focusing on the mitochondria isolated from lymphocytes we may be able to overcome this limitation.

Taken together, the results of this study suggest that the elevated oxidative stress markers in the mitochondria from lymphocytes may potentially reflect the brain damage in AD and may potentially serve as a marker for AD diagnosis or treatment.

In conclusion, our study demonstrates that AD is associated with elevated levels of oxidative damage in mitochondria from peripheral lymphocytes, as well as the previously-reported neuronal damage, and suggests a mitochondrial functional impairment in AD lymphocytes. We also demonstrated that peripheral tissue, such as lymphocytes, could potentially offer a simple alternative method to detect increased free radical damage in AD, and demonstrated that oxidative stress in AD is present not only in neuronal tissues but also in peripheral lymphocytes. Further, an inverse correlation of the oxidative markers in mitochondria from peripheral lymphocytes with MMSE scores suggests that peripheral lymphocytes could serve as a tool to index the cognitive alteration in AD. Investigation of the protein expression differences between control and AD mitochondria isolated from lymphocytes, with the purpose to further elucidate the mechanisms

of A β -induced oxidative damage, is being pursued in our laboratory. The present studies suggest that oxidative stress in mitochondria from peripheral lymphocytes from subjects with AD may represent a viable biomarker for AD. Of course, additional studies with MCI and with other neurodegenerative disorders will be necessary to validate this notion. However, the present studies represent a baseline from which other conditions can be compared for this purpose.

ACKNOWLEDGMENTS

This work was supported in part by a grant from the National Institutes of Health AG-05119 to D.A.B. and PRIN 2007 grant to P.M.

Authors' disclosures available online (<http://www.jalz.com/disclosures/view.php?id=674>).

REFERENCES

- [1] Kurz T, Terman A, Brunk UT (2007) Autophagy, ageing and apoptosis: the role of oxidative stress and lysosomal iron. *Arch Biochem Biophys* **462**, 220-230.
- [2] Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* **81**, 741-766.
- [3] Boyd-Kimball D, Mohammad Abdul H, Reed T, Sultana R, Butterfield DA (2004) Role of phenylalanine 20 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. *Chem Res Toxicol* **17**, 1743-1749.
- [4] Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA (2005) Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: implications for Alzheimer's disease. *Neuroscience* **132**, 313-324.
- [5] Butterfield DA, Boyd-Kimball D (2005) The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. *Biochim Biophys Acta* **1703**, 149-156.
- [6] Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, Bredesen DE (2010) *In vivo* oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. *Free Radic Biol Med* **48**, 136-144.
- [7] Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. *Free Radic Biol Med* **23**, 134-147.
- [8] Fukuda M, Kanou F, Shimada N, Sawabe M, Saito Y, Murayama S, Hashimoto M, Maruyama N, Ishigami A (2009) Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease. *Biomed Res* **30**, 227-233.
- [9] Markesbery WR, Lovell MA (1998) 4-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. *Neurobiol Aging* **19**, 33-36.
- [10] Mecocci P, Polidori MC, Cherubini A, Ingegnoli T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF (2002) Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. *Arch Neurol* **59**, 794-798.

- [11] Montine KS, Olson SJ, Amarnath V, Whetsell WO Jr, Graham DG, Montine TJ (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. *Am J Pathol* **150**, 437-443.
- [12] Pratico D, Sung S (2004) Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. *J Alzheimers Dis* **6**, 171-175.
- [13] Volkel W, Sicilia T, Pahlér A, Gsell W, Tatschner T, Jellinger K, Leblhuber F, Riederer P, Lutz WK, Gotz ME (2006) Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. *Neurochem Int* **48**, 679-686.
- [14] Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA (1998) Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. *J Neurosci* **18**, 8126-8132.
- [15] Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. *J Neurochem* **78**, 413-416.
- [16] Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G (2008) Nucleic acid oxidation in Alzheimer disease. *Free Radic Biol Med* **44**, 1493-1505.
- [17] Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, Yamaguchi H, Shimohama S, Lee HG, Zhu X, Smith MA, Perry G (2010) Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. *Neurobiol Dis* **37**, 731-737.
- [18] Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. *Faseb J* **19**, 2040-2041.
- [19] Reddy PH (2009) Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. *Exp Neurol* **218**, 286-292.
- [20] Sultana R, Butterfield DA (2009) Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. *J Bioenerg Biomembr* **41**, 441-446.
- [21] Ankarcona M, Mangialasche F, Winblad B (2010) Rethinking Alzheimer's disease therapy: are mitochondria the key? *J Alzheimers Dis* **20**(Suppl 2), S579-S590.
- [22] Gustaw-Rothenberg K, Lerner A, Bonda DJ, Lee HG, Zhu X, Perry G, Smith MA (2010) Biomarkers in Alzheimer's disease: past, present and future. *Biomark Med* **4**, 15-26.
- [23] Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L (2005) Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. *Neurobiol Aging* **26**, 587-595.
- [24] Gibson GE, Zhang H (2001) Abnormalities in oxidative processes in non-neuronal tissues from patients with Alzheimer's disease. *J Alzheimers Dis* **3**, 329-338.
- [25] Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189-198.
- [26] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **34**, 939-944.
- [27] Sultana R, Ravagna A, Mohammad-Abdul H, Calabrese V, Butterfield DA (2005) Ferulic acid ethyl ester protects neurons against amyloid beta-peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. *J Neurochem* **92**, 749-758.
- [28] Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* **11**, 81-128.
- [29] Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease, and oxidative stress. *J Biol Chem* **272**, 20313-20316.
- [30] Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. *Neurobiol Aging* **23**, 655-664.
- [31] Butterfield DA, Stadtman ER (1997) Protein oxidation processes in aging brain. *Adv Cell Aging Gerontol* **2**, 161-191.
- [32] Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, Butterfield DA (2006) Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. *Antioxid Redox Signal* **8**, 1975-1986.
- [33] Mecocci P, Polidori MC, Ingegneri T, Cherubini A, Chionne F, Cecchetti R, Senin U (1998) Oxidative damage to DNA in lymphocytes from AD patients. *Neurology* **51**, 1014-1017.
- [34] Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M (2008) Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. *Brain Res* **1219**, 169-179.
- [35] Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. *Arch Neurol* **60**, 958-964.
- [36] Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. *Amyloid* **7**, 245-258.
- [37] Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. *Ann Neurol* **45**, 537-541.
- [38] Glabe CC (2005) Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. *Subcell Biochem* **38**, 167-177.
- [39] Molina JA, de Bustos F, Jimenez-Jimenez FJ, Benito-Leon J, Gasalla T, Orti-Pareja M, Vela L, Bermejo F, Martin MA, Campos Y, Arenas J (1997) Respiratory chain enzyme activities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. *Neurology* **48**, 636-638.
- [40] Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G (2007) Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. *J Alzheimers Dis* **12**, 195-206.
- [41] Crouch PJ, Cimdins K, Duce JA, Bush AI, Trounce IA (2007) Mitochondria in aging and Alzheimer's disease. *Rejuvenation Res* **10**, 349-357.
- [42] Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S (2009) Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. *Curr Alzheimer Res* **6**, 312-319.

- [43] Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. *Free Radic Biol Med* **33**, 562-571.
- [44] Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. *J Neurochem* **82**, 1524-1532.
- [45] Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. *J Neurochem* **85**, 1394-1401.
- [46] Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnesic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. *Neurobiol Dis* **30**, 107-120.
- [47] Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. *Neurobiol Aging* **27**, 1564-1576.
- [48] Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA (2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. *Neurobiol Dis* **22**, 76-87.
- [49] Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, Butterfield DA (2009) Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. *Proteomics Clin Appl* **3**, 682-693.
- [50] Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. *Ann Neurol* **57**, 695-703.
- [51] Sims NR (1990) Altered glucose metabolism in Alzheimer's disease. *Ann Neurol* **27**, 691-693.
- [52] Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. *J Neurochem* **80**, 91-100.
- [53] Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ, 2nd, Kaye JA, Morrow JD (2002) Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. *Ann Neurol* **52**, 175-179.